Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector

Molecular Therapy

Volumn 8, Issue 5, 2003, Pages 813-821

  Sakurai, Fuminori ^a   Mizuguchi, Hiroyuki ^a   Yamaguchi, Teruhide ^a   Hayakawa, Takao ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

Adenovirus serotype 35 vector; Biodistribution; CAR; Gene therapy; Liver nonparenchymal cells; Liver parenchymal cells

Indexed keywords

ADENOVIRUS VECTOR; VIRUS PROTEIN; VIRUS RECEPTOR;

ANIMAL TISSUE; BLOOD FLOW; CONTROLLED STUDY; COXSACKIE VIRUS; FEMALE; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER PARENCHYMA; MOUSE; NONHUMAN; REVIEW; SEROTYPE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALIA; COXSACKIEVIRUS;

EID: 0346872988     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-0016(03)00243-0     Document Type: Article

References (73)

1. Kovesdi, I., Brough, D. E., Bruder, J. T., and Wickham, T. J. (1997). Adenoviral vectors for gene transfer. Curr. Opin. Biotechnol. 8: 583-589.
2. Yeh, P., and Perricaudet, M (1997). Advances in adenoviral vectors: from genetic engineering to their biology. FASEB J. 11: 615-623.
3. Benihoud, K., Yeh, P., and Perricaudet, M. (1999). Adenovirus vectors for gene delivery. Curr. Opin. Biotechnol. 10: 440-447.
4. Havenga, M. J., et al. (2002). Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J. Virol. 76: 4612-4620.
5. De Jong, J. C., et al. (1999). Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively. J. Clin. Microbiol. 37: 3940-3945.
6. Bergelson, J. M., et al. (1997). Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275: 1320-1323.
7. Tomko, R. P., Xu, R., and Philipson, L. (1997). HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl. Acad. Sci. USA 94: 3352-3356.
8. Li, Y., et al. (1999). Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res. 59: 325-330.
9. Hemmi, S., et al. (1998). The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum. Gene Ther. 9: 2363-2373.
10. Koizumi, N., et al. (2001). Efficient gene transfer by fiber-mutant adenoviral vectors containing RGD peptide. Biochim. Biophys. Acta. 1568: 13-20.
11. Miller, C. R., et al. (1998). Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res. 58: 5738-5748.
12. Nalbantoglu, J., Pari, G., Karpati, G., and Holland, P. C. (1999). Expression of the primary coxsackie and adenovirus receptor is downregulated during skeletal muscle maturation and limits the efficacy of adenovirus-mediated gene delivery to muscle cells. Hum. Gene Ther. 10: 1009-1019.
13. Okada, N., et al. (2001). Efficient gene delivery into dendritic cells by fiber-mutant adenovirus vectors. Biochem. Biophys. Res. Commun. 282: 173-179.
14. Tillman, B. W., et al. (1999). Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. J. Immunol. 162: 6378-6383.
15. Shayakhmetov, D. M., Papayannopoulou, T., Stamatoyannopoulos, G., and Lieber, A. (2000). Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J. Virol. 74: 2567-2583.
16. Einfeld, D. A., et al. (2001). Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J. Virol. 75: 11284-11291.
17. Bergelson, J. M., et al. (1998). The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J. Virol. 72: 415-419.
18. Fechner, H., et al. (1999). Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther. 6: 1520-1535.
19. Roelvink, P. W., et al. (1998). The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J. Virol. 72: 7909-7915.
20. Stecher, H., Shayakhmetov, D. M., Stamatoyannopoulos, G., and Lieber, A. (2001). A capsid-modified adenovirus vector devoid of all viral genes: assessment of transduction and toxicity in human hematopoietic cells. Mol. Ther. 4; 36-44.
21. Gall, J., Kass-Eisler, A., Leinwand, L., and Falck-Pedersen, E. (1996). Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J. Virol. 70: 2116-2123.
22. Mizuguchi, H., and Hayakawa, T. (2002). Adenovirus vectors containing chimeric type 5 and type 35 fiber proteins exhibit altered and expanded tropism and increase the size limit of foreign genes. Gene 285: 69-77.
23. Kanerva, A., et al. (2002). Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol. Ther. 5: 695-704.
24. Myerowitz, R. L., et al. (1975). Fatal disseminated adenovirus infection in a renal transplant recipient. Am. J. Med. 59: 591-598.
25. Chroboczek, J., Ruigrok, R. W. H., and Cusack, S. (1995). Adenovirus fiber. In The Molecular Repertoire of Adenoviruses (P. B. W. Doerfler, Ed.), Vol. 1, pp.163-200. Springer-Verlag, Berlin.
26. Segerman, A., Mei, Y. F., and Wadell, G. (2000). Adenovirus types 11p and 35p show high binding efficiencies for committed hematopoietic cell lines and are infective to these cell lines. J. Virol. 74: 1457-1467.
27. + cells by an adenovirus type 35 vector. Gene Ther. 10:1041-1048.
28. Krougliak, V., and Graham, F. L. (1995). Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants. Hum. Gene Ther. 6: 1575-1586.
29. Mizuguchi, H., and Kay, M. A. (1998). Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum. Gene Ther. 9: 2577-2583.
30. Mizuguchi, H., and Kay, M. A. (1999). A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. Hum. Gene Ther. 10: 2013-2017.
31. Kanegae, Y., Makimura, M., and Saito, I. (1994). A simple and efficient method for purification of infectious recombinant adenovirus. Jpn. J. Med. Sci. Biol. 47: 157-166.
32. Maizel, J. V. Jr., White, D. O., and Scharff, M. D. (1968). The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 36: 115-125.
33. Xu, Z. L., et al. (2001). Optimization of transcriptional regulatory elements for constructing plasmid vectors. Gene 272: 149-156.
34. Alemany, R., Suzuki, K., and Curiel, D. T. (2000). Blood clearance rates of adenovirus type 5 in mice. J. Gen. Virol. 81: 2605-2609.
35. Mizuguchi, H., et al. (2001). A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Ther. 8: 730-735.
36. Nishikawa, M., Takemura, S., Takakura, Y., and Hashida, M. (1998). Targeted delivery of plasmid DNA to hepatocytes in vivo: optimization of the pharmacokinetics of plasmid DNA/galactosylated poly(L-lysine) complexes by controlling their physicochemical properties. J. Pharmacol. Exp. Ther. 287: 408-415.
37. Aoki, K., et al. (2001). Polyethylenimine-mediated gene transfer into pancreatic tumor dissemination in the murine peritoneal cavity. Gene Ther. 8: 508-514.
38. Peng, K. W., et al. (2001). Organ distribution of gene expression after intravenous infusion of targeted and untargeted lentiviral vectors. Gene Ther. 8: 1456-1463.
39. Asaoka, K., et al. (2000). Dependence of efficient adenoviral gene delivery in malignant glioma cells on the expression levels of the coxsackievirus and adenovirus receptor. J. Neurosurg. 92: 1002-1008.
40. Dechecchi, M. C., et al. (2001). Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J. Virol. 75: 8772-8780.
41. Ebbinghaus, C., et al. (2001). Functional and selective targeting of adenovirus to high-affinity Fcgamma receptor I-positive cells by using a bispecific hybrid adapter. J. Virol. 75: 480-489.
42. Huard, J., et al. (1995). The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther. 2: 107-115.
43. Wood, M., et al. (1999). Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse. Cancer Gene Ther. 6: 367-372.
44. Worgall, S., Wolff, G., Falck-Pedersen, E., and Crystal, R. G. (1997). Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum. Gene Ther. 8: 37-44.
45. Blomhoff, R., et al. (1985). Uptake and degradation of bovine testes beta-galactosidase by parenchymal and nonparenchymal rat liver cells. Int. J. Biochem. 17: 1321-1328.
46. Abrahamsen, K., et al. (1997). Construction of an adenovirus type 7a EIA- vector. J. Virol. 71: 8946-8951.
47. Wu, H., et al. (2002). Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. J. Virol. 76: 12775-12782.
48. Gall, J. G., Crystal, R. G., and Falck-Pedersen, E. (1998). Construction and characterization of hexon-chimeric adenoviruses: specification of adenovirus serotype. J. Virol. 72: 10260-10264.
49. Shayakhmetov, D. M., Li, Z. Y., Ni, S., and Lieber, A. (2002). Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer Res. 62: 1063-1068.
50. Rea, D., et al. (2001). Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J. Immunol. 166: 5236-5244.
51. Segerman, A., et al. (2003). There are two different species B adenovirus receptors: sBAR, common to species B1 and B2 adenoviruses, and sB2AR, exclusively used by species B2 adenoviruses. J. Virol. 77: 1157-1162.
52. Arnberg, N., Mei, Y., and Wadell, G. (1997). Fiber genes of adenoviruses with tropism for the eye and the genital tract. Virology 227: 239-244.
53. Wake, K., et al. (1989). Cell biology and kinetics of Kupffer cells in the liver. Int. Rev. Cytol. 118: 173-229.
54. Hegenbarth, S., et al. (2000). Liver sinusoidal endothelial cells are not permissive for adenovirus type 5. Hum. Gene Ther. 11: 481-486.
55. Shayakhmetov, D. M., et al. (2003). The interaction between the fiber knob domain and the cellular attachment receptor determines the intracellular trafficking route of adenoviruses. J. Virol. 77: 3712-3723.
56. Seth, P. (1994). Adenovirus-dependent release of choline from plasma membrane vesicles at an acidic pH is mediated by the penton base protein. J. Virol. 68: 1204-1206.
57. Wickham, T. J., Filardo, E. J., Cheresh, D. A., and Nemerow, G. R. (1994). Integrin alpha v beta 5 selectively promotes adenovirus mediated cell membrane permeabilization. J. Cell. Biol. 127: 257-264.
58. Defer, C., Belin, M. T., Caillet-Boudin, M. L., and Boulanger, P. (1990). Human adenovirus-host cell interactions: comparative study with members of subgroups B and C. J. Virol. 64: 3661-3673.
59. Wickham, T. J., Mathias, P., Cheresh, D. A., and Nemerow, G. R. (1993). Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73: 309-319.
60. Mizuguchi, H., et al. (2002). CAR- or alphav integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice. Gene Ther. 9: 769-776.
61. Hidaka, C., et al. (1999). CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts. J. Clin. Invest. 103: 579-587.
62. Vigne, E., et al. (2003). Genetic manipulations of adenovirus type 5 fiber resulting in liver tropism attenuation. Gene Ther. 10: 153-162.
63. Trotman, L. C., et al. (2001). Import of adenovirus DNA involves the nuclear pore complex receptor CAN/Nup214 and histone H1. Nat. Cell Biol. 3: 1092-1100.
64. Saphire, A. C., et al. (2000). Nuclear import of adenovirus DNA in vitro involves the nuclear protein import pathway and hsc70. J. Biol. Chem. 275: 4298-4304.
65. Crawford-Miksza, L., and Schnurr, D. P. (1996). Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues. J. Virol. 70: 1836-1844.
66. Schulick, A. H., et al. (1997). Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity. J. Clin. Invest. 99: 209-219.
67. Brann, T., et al. (2002). Evaluation of human antibody neutralization, biodistribution, and transduction mechanisms of adenovirus serotype 35. Mol. Ther. 5: S316 [Abstract].
68. Roy, S., Shirley, P. S., McClelland, A., and Kaleko, M. (1998). Circumvention of immunity to the adenovirus major coat protein hexon. J. Virol. 72: 6875-6879.
69. Francois, A., et al. (2001). Construction of avian adenovirus CELO recombinants in cosmids. J. Virol. 75: 5288-5301.
70. Nguyen, T., et al. (1999). Mouse adenovirus (MAV-1) expression in primary human endothelial cells and generation of a full-length infectious plasmid. Gene Ther. 6: 1291-1297.
71. Kremer, E. J., Boutin, S., Chillon, M., and Danos, O. (2000). Canine adenovirus vectors: an alternative for adenovirus-mediated gene transfer. J. Virol. 74: 505-512.
72. Reddy, P. S., et al. (1999). Replication-defective bovine adenovirus type 3 as an expression vector. J. Virol. 73: 9137-9144.
73. Farina, S. F., et al. (2001). Replication-defective vector based on a chimpanzee adenovirus. J. Virol. 75: 11603-11613.